This evidence indicates that Nr4a1 is responsible for defects caused by SNRPN knockdown and that pharmacological inhibition of Nr4a1 is a potential therapeutic target for SNRPN-related brain disorders. The gene discussed is NR4A1; the disease is brain disorder.